Literature DB >> 15741978

Adverse events after botulinum A toxin injection for neurogenic voiding disorders.

K De Laet1, J-J Wyndaele.   

Abstract

OBJECTIVES: To review the side effects of local injections of botulinum A toxin (BTX-A).
METHODS: A medline search for publications about adverse events after injection of BTX-A for lower urinary tract dysfunctions.
RESULTS: We found four publications that report generalised side effects after BTX-A injection for detrusor overactivity (two) and detrusor-sphincter dyssynergia (two). The causes of generalised adverse events are not clear, but spread outside the target organ and into the systemic circulation may contribute. The dose used, the injection volume and the injection technique can all play a role.
CONCLUSION: Generalised side effects after BTX-A injection for voiding disorders are rare but they can be very disabling for spinal cord-injured patients. Although no long-term side effects are reported so far, urologists should be aware that these effects of BTX-A injections are unknown.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741978     DOI: 10.1038/sj.sc.3101736

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  15 in total

Review 1.  Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults.

Authors:  Douglas G Tincello
Journal:  World J Urol       Date:  2011-10-15       Impact factor: 4.226

Review 2.  [Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction].

Authors:  K-D Sievert; J Bremer; H Burgdörfer; B Domurath; C Hampel; J Kutzenberger; C Seif; M Stöhrer; B Wefer; J Pannek
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

Review 3.  OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

4.  Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection.

Authors:  Mazen Alsinnawi; William Torreggiani; Mazher Sheikh; Arun Thomas; John Donnellan; Robert Flynn; T E D Mcdermott; John Thornhill
Journal:  Int Urol Nephrol       Date:  2015-04-19       Impact factor: 2.370

Review 5.  The use of botulinum toxin a in idiopathic overactive bladder syndrome.

Authors:  Christopher S Gomez; Prashanth Kanagarajah; Angelo Gousse
Journal:  Curr Urol Rep       Date:  2010-09       Impact factor: 3.092

Review 6.  Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice.

Authors:  Stephanie Knuepfer; Klaus-Peter Juenemann
Journal:  Ther Adv Urol       Date:  2014-02

7.  Focal arm weakness following intradetrusor botulinum toxin administration in spinal cord injury: Report of two cases.

Authors:  Christopher Goodrich; Henry York; Andrew Shapiro; Peter Howard Gorman
Journal:  J Spinal Cord Med       Date:  2019-01-31       Impact factor: 1.985

Review 8.  The use of botulinum neurotoxin type A (BoNTA) in urology.

Authors:  A Apostolidis; C J Fowler
Journal:  J Neural Transm (Vienna)       Date:  2008-03-06       Impact factor: 3.575

9.  OnabotulinumtoxinA in the treatment of neurogenic bladder.

Authors:  Aziz Gulamhusein; Altaf Mangera
Journal:  Biologics       Date:  2012-08-28

10.  Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.

Authors:  Cristian Sager; Carol Burek; Victor Durán; Juan Pablo Corbetta; Santiago Weller; Bortagaray Juan; Juan Carlos López
Journal:  ISRN Urol       Date:  2012-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.